37,800 Shares in BioCryst Pharmaceuticals, Inc. $BCRX Purchased by Strs Ohio

Strs Ohio bought a new position in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) in the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund bought 37,800 shares of the biotechnology company’s stock, valued at approximately $284,000.

Several other hedge funds and other institutional investors have also modified their holdings of BCRX. Millennium Management LLC boosted its holdings in shares of BioCryst Pharmaceuticals by 382.6% during the 1st quarter. Millennium Management LLC now owns 3,812,874 shares of the biotechnology company’s stock worth $28,597,000 after buying an additional 3,022,769 shares during the period. Nuveen LLC bought a new stake in BioCryst Pharmaceuticals in the 1st quarter valued at about $10,677,000. Jupiter Asset Management Ltd. boosted its holdings in BioCryst Pharmaceuticals by 82.4% in the 1st quarter. Jupiter Asset Management Ltd. now owns 2,148,969 shares of the biotechnology company’s stock valued at $16,117,000 after purchasing an additional 971,040 shares during the period. Parkman Healthcare Partners LLC boosted its holdings in BioCryst Pharmaceuticals by 361.3% in the 1st quarter. Parkman Healthcare Partners LLC now owns 1,000,562 shares of the biotechnology company’s stock valued at $7,504,000 after purchasing an additional 783,681 shares during the period. Finally, Goldman Sachs Group Inc. boosted its holdings in BioCryst Pharmaceuticals by 49.6% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,931,934 shares of the biotechnology company’s stock valued at $14,490,000 after purchasing an additional 640,704 shares during the period. Institutional investors own 85.88% of the company’s stock.

Insider Transactions at BioCryst Pharmaceuticals

In other BioCryst Pharmaceuticals news, Director Theresa Heggie sold 70,000 shares of the company’s stock in a transaction that occurred on Wednesday, August 13th. The shares were sold at an average price of $8.51, for a total value of $595,700.00. Following the completion of the transaction, the director directly owned 65,352 shares in the company, valued at approximately $556,145.52. This represents a 51.72% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 5.10% of the company’s stock.

BioCryst Pharmaceuticals Stock Performance

Shares of NASDAQ BCRX opened at $7.82 on Wednesday. BioCryst Pharmaceuticals, Inc. has a 52-week low of $6.01 and a 52-week high of $11.31. The firm has a 50 day moving average price of $8.28 and a two-hundred day moving average price of $8.71. The stock has a market cap of $1.64 billion, a P/E ratio of -43.44, a price-to-earnings-growth ratio of 1.59 and a beta of 1.13.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its quarterly earnings results on Monday, August 4th. The biotechnology company reported $0.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.03 by $0.12. The business had revenue of $163.35 million during the quarter, compared to analyst estimates of $149.59 million. During the same quarter last year, the company posted ($0.06) earnings per share. The company’s revenue was up 49.5% compared to the same quarter last year. Analysts predict that BioCryst Pharmaceuticals, Inc. will post -0.36 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on BCRX. Wedbush boosted their price objective on shares of BioCryst Pharmaceuticals from $16.00 to $18.00 and gave the company an “outperform” rating in a report on Monday, June 30th. Wall Street Zen raised shares of BioCryst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Saturday, July 26th. Bank of America boosted their price objective on shares of BioCryst Pharmaceuticals from $13.00 to $15.00 and gave the company a “buy” rating in a report on Tuesday, July 1st. Royal Bank Of Canada reissued an “outperform” rating and issued a $13.00 price objective on shares of BioCryst Pharmaceuticals in a report on Monday, June 30th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $17.00 price objective on shares of BioCryst Pharmaceuticals in a report on Monday, August 4th. Nine analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $16.70.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.